A compendium of co-regulated mitoribosomal proteins in pan-cancer uncovers collateral defective events in tumor malignancy

Chang, Chiung‐Fang; Zhuang, W.; Durell, Stewart R.; Ma, Lichun; Forgues, Marshonna; Wang, Xin Wei

doi:10.1016/j.isci.2022.105244

iScience

2022

DOI: 10.1016/j.isci.2022.105244

|View full text |Cite

A compendium of co-regulated mitoribosomal proteins in pan-cancer uncovers collateral defective events in tumor malignancy

Chiung‐Fang Chang¹,

W. Zhuang²,

Stewart R. Durell³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets

Bacon,

Jones,

Liu

et al. 2024

Cancer Metastasis Rev

View full text Add to dashboard Cite

The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.

show abstract

Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets

Bacon,

Jones,

Liu

et al. 2024

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity

Zhao

Cui

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A compendium of co-regulated mitoribosomal proteins in pan-cancer uncovers collateral defective events in tumor malignancy

Cited by 2 publications

References 52 publications

Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets

Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets

The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity

Contact Info

Product

Resources

About